Premature Ovarian Failure Clinical Trial
Official title:
Levels of Zinc (Zn), Copper (Cu), Calcium (Ca), Iron (Fe), Manganese (Mn), Selenium (Se), Strontium (Sr), Aluminium (Al), Antimonium (Sb), Phosphorus (P), Magnesium (Mg), Sodium (Na), Potassium (K), Barium (Ba) and Thallium (Tl) in Idiopathic Premature Ovarian Failure
Aim: To evaluate plasma zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) levels in women with premature ovarian insufficiency (POI) and to compare the results with those of healthy subjects. Methods: This prospective study will be included 70 women with idiopathic premature ovarian insufficiency and 70 controls. The blood/urine/hair for analyses will be obtained at the early follicular phase of the menstrual cycle and plasma zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) levels will be measured using inductively coupled plasma-mass spectrometry.
This will be an observational prospective cohort study conducted at Obstetrics and Gynecology Department of Cengiz Gokcek Obstetrics and Children's Hospital between January 2020 and September 2021. The authors will be recruited 70 subjects with idiopathic POI, and 70 healthy patients were selected for the control group. All patients will be given their oral and written informed consent before their inclusion in the study. The protocol was approved by the Ethics Committee for Clinical Research of Gaziantep University (Reference number: 2021/343). The study strictly will be adhered to the principles of the Declaration of Helsinki. Women between the ages of 18-39 will be included. A volunteer group of healthy women who will be visited the gynecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group. Healthy women, who will be returned during their early follicular phase of the menstrual cycle, will be recruited as the control group subjects. The exclusion criteria will be as follows: women with evidence for karyotypic, metabolic, toxic, or iatrogenic cause of the ovarian insufficiency and any women who use any medication for POI treatment. At enrollment, for both groups, the authors will be collected data about age, height, weight, BMI, age of menarche, obstetrics history, history of smoking, regular exercise and family history of POI. At enrolment, all patients will be underwent vaginal ultrasonography for the assessment of antral follicle count (AFC) and venous blood sample from the antecubital veins for measuring plasma concentration of zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl), Follicle-stimulating hormone (FSH), E2, anti-mullerian hormone (AMH) and complete blood count (CBC). In control subjects, venous blood samples and AFC will be collected during the early follicular phase of the menstrual cycle. Urine and hair samples will be collected at the same time. The plasma and urine samples will be stored in aliquots at -80°C prior to the analyses of zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl). Hair samples will be stored in envelopes at room temperature. The plasma/urine/hair zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) level will be measured using inductively coupled plasma-mass spectrometry. Then, this study will be determined plasma/urine/hair zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) levels in women with POI (n=70) compared to those of volunteer healthy women (n=70). Then, these macroelements levels will be compared in both groups. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Unknown status |
NCT01853501 -
Effects of ADSC Therapy in Women With POF
|
Phase 4 | |
Completed |
NCT00417066 -
Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
|
Phase 4 | |
Active, not recruiting |
NCT04675970 -
Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy
|
||
Recruiting |
NCT03480412 -
Second Step Protocol in Poor Ovarian Responder (POR)
|
||
Completed |
NCT02644447 -
Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
|
Phase 1/Phase 2 | |
Completed |
NCT03840824 -
Blood Spot Self-administered Test and Assay
|
||
Recruiting |
NCT00119925 -
'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists"
|
N/A | |
Recruiting |
NCT06117982 -
The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
|
Phase 2 | |
Suspended |
NCT03816852 -
The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
|
Phase 2 | |
Not yet recruiting |
NCT04390308 -
Is There A Role For Mechanical Stimulation In Ovarian Follicular Activation?
|
||
Completed |
NCT02783937 -
Filgrastim for Premature Ovarian Insufficiency
|
Phase 4 | |
Completed |
NCT00295087 -
X-Chromosome Inactivation Status and Premature Ovarian Failure
|
N/A | |
Completed |
NCT00429494 -
GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
|
Phase 2 | |
Not yet recruiting |
NCT05522634 -
A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
|
Early Phase 1 | |
Recruiting |
NCT05838157 -
The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age
|
||
Withdrawn |
NCT01129947 -
The Use of DHEA in Women With Premature Ovarian Failure
|
Phase 0 | |
Completed |
NCT00001275 -
Ovarian Follicle Function in Patients With Primary Ovarian Failure
|
N/A | |
Not yet recruiting |
NCT04306185 -
Ovarian Fragmentation Study (Crespo Medical Team)
|
N/A | |
Recruiting |
NCT02062931 -
Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
|
Phase 1/Phase 2 | |
Completed |
NCT02151890 -
Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
|
Phase 1/Phase 2 |